US EditionMIRA secures board approval to buy SKNY Pharmaceuticals
Summary by Pharmaceutical Business Review
2 Articles
2 Articles
All
Left
Center
1
Right
EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Mira Pharmaceuticals (NASDAQ:MIRA)
Mira Pharmaceuticals to acquire SKNY in a stock-based deal valuing both firms near $30 million each, backed by third-party pipeline valuation reports.
·New York, United States
Read Full Article
MIRA secures board approval to buy SKNY Pharmaceuticals
The strategic decision follows thorough independent valuations of both entities, with the merger contingent upon approval from shareholders of both companies. Moore Financial Consulting conducted a third-party analysis The post MIRA secures board approval to buy SKNY Pharmaceuticals appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage